Cesar A. Arias, MD, MSc, PhD

John F. III and Ann H. Bookout Distinguished Chair for Research Excellence, Research Institute
Professor of Medicine, Academic Institute
Full Member, Research Institute
Co-director, Center for Infectious Diseases Research
Houston Methodist


Dr. Cesar Arias has over 25 years of experience in the field of antimicrobial resistance. His career has focused on the clinical and molecular aspects of antimicrobial resistance (AMR) with emphasis on gram-positive organisms. He became interested in infectious disease (ID) because of its prominence as a public health problem and also because ID spans all aspects of clinical medicine. After medical school, he attended the University of London where he focused on clinical microbiology and performed research on the molecular biology of capsule genes in S. pneumoniae, developing molecular tools for capsule typing of this important pathogen. He obtained his PhD at Cambridge in 2000, studying the molecular mechanisms of vancomycin resistance in enterococci. During graduate studies, he discovered a new enzyme and elucidated a novel mechanism for synthesis of D-serine in bacteria. After completing residency at UTHealth McGovern Medical School as well as a fellowship in ID (joint program with UT MD Anderson Cancer Center), he expanded studies on staphylococci and enterococci.

He was the recipient of a K99/R00 NIH Pathway to Independence Award and now holds an NIH K24 mid-career investigator award to increase patient-oriented and mentoring activities on antimicrobial resistance. He has also founded two overseas research units (Molecular Genetics and Antimicrobial Resistance Unit and the International Center for Microbial Genomics) focused on AMR at Universidad El Bosque, Bogota, Colombia. His most recent research has concentrated on elucidating the mechanistic basis of resistance to daptomycin with focus on enterococci and to dissect the molecular epidemiology and clinical impact of multidrug-resistant organisms as part of the NIH-funded Antimicrobial Resistance Leadership Group. A major component of the research on MDR organisms is the use of genomics as a major tool to dissect the molecular epidemiology and population structure of MDR bacteria.


Consensus on b-Lactamase Nomenclature
Bradford, PA, Bonomo, RA, Bush, K, Carattoli, A, Feldgarden, M, Haft, DH, Ishii, Y, Jacoby, GA, Klimke, W, Palzkill, T, Poirel, L, Rossolini, GM, Tamma, PD & Arias, CA 2022, , Antimicrobial Agents and Chemotherapy, vol. 66, no. 4. https://doi.org/10.1128/aac.00333-22

Reply to Kaye and Belley, "Third-Generation Cephalosporin- Resistant Enterobacterales Are Critical Priority Pathogens, Too!"
Butler, MS, Gigante, V, Sati, H, Paulin, S, Al-Sulaiman, L, Rex, JH, Fernandes, P, Arias, CA, Paul, M, Thwaites, GE, Czaplewski, L, Alm, RA, Lienhardt, C, Spigelman, M, Silver, LL, Ohmagari, N, Kozlov, R, Harbarth, S & Beyer, P 2022, , Antimicrobial Agents and Chemotherapy, vol. 66, no. 4. https://doi.org/10.1128/aac.00223-22

Accessory Genomes Drive Independent Spread of Carbapenem- Resistant Klebsiella pneumoniae Clonal Groups 258 and 307 in Houston, TX
Shropshire, WC, Dinh, AQ, Earley, M, Komarow, L, Panesso, D, Rydell, K, Gómez-Villegas, SI, Miao, H, Hill, C, Chen, L, Patel, R, Fries, BC, Abbo, L, Cober, E, Revolinski, S, Luterbach, CL, Chambers, H, Fowler, VG, Bonomo, RA, Shelburne, S, Kreiswirth, BN, van Duin, D, Hanson, BM & Arias, CA 2022, , mBio, vol. 13, no. 2, pp. e0049722. https://doi.org/10.1128/mbio.00497-22

Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed
Butler, MS, Gigante, V, Sati, H, Paulin, S, Al-Sulaiman, L, Rex, JH, Fernandes, P, Arias, CA, Paul, M, Thwaites, GE, Czaplewski, L, Alm, RA, Lienhardt, C, Spigelman, M, Silver, LL, Ohmagari, N, Kozlov, R, Harbarth, S & Beyer, P 2022, , Antimicrobial Agents and Chemotherapy, vol. 66, no. 3, e01991-21. https://doi.org/10.1128/aac.01991-21

Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study
Multi-Drug Resistant Organism Network Investigators 2022, , The Lancet Infectious Diseases, vol. 22, no. 3, pp. 401-412. https://doi.org/10.1016/S1473-3099(21)00399-6

Evaluation of Bacteriophage-Antibiotic Combination Therapy for Biofilm-Embedded MDR Enterococcus faecium
Lev, K, Coyne, AJK, Kebriaei, R, Morrisette, T, Stamper, K, Holger, DJ, Canfield, GS, Duerkop, BA, Arias, CA & Rybak, MJ 2022, , Antibiotics, vol. 11, no. 3, 392. https://doi.org/10.3390/antibiotics11030392

Contemporary Clinical and Molecular Epidemiology of Vancomycin-Resistant Enterococcal Bacteremia: A Prospective Multicenter Cohort Study (VENOUS I)
Contreras, GA, Munita, JM, Simar, S, Luterbach, C, Dinh, AQ, Rydell, K, Sahasrabhojane, PV, Rios, R, Diaz, L, Reyes, K, Zervos, M, Misikir, HM, Sanchez-Petitto, G, Liu, C, Doi, Y, Abbo, LM, Shimose, L, Seifert, H, Gudiol, C, Barberis, F, Pedroza, C, Aitken, SL, Shelburne, SA, Van Duin, D, Tran, TT, Hanson, BM & Arias, CA 2022, , Open Forum Infectious Diseases, vol. 9, no. 3, ofab616. https://doi.org/10.1093/ofid/ofab616

LiaX is Essential for Cell Envelope Adaptation via the LiaFSR System in Enterococcus faecium
Tran, C, Arias, CA & Panesso, D 2022, , 5th Texas Medical Center Conference on Antimicrobial Resistance and Stewardship Conference, Houston, United States, 1/19/22 - 1/21/22.

Emergence of Clinical Clostridioides difficile Isolates With Decreased Susceptibility to Vancomycin
Darkoh, C, Keita, K, Odo, C, Oyaro, M, Brown, EL, Arias, CA, Hanson, BM & DuPont, HL 2022, , Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol. 74, no. 1, pp. 120-126. https://doi.org/10.1093/cid/ciaa912

Real-World Performance of Susceptibility Testing for Ceftolozane/Tazobactam against Non-Carbapenemase- Producing Carbapenem-Resistant Pseudomonas aeruginosa
Rivas, L, Alcalde-Rico, M, Martínez, JRW, Moreno, MV, Rojas, P, Wozniak, A, García, P, Olivares-Pacheco, J, Miller, WR, Arias, CA, Khan, A & Munita, JM 2022, , Antimicrobial Agents and Chemotherapy, vol. 66, no. 1, e01657-21. https://doi.org/10.1128/AAC.01657-21

Evaluation of Bacteriophage Cocktails Alone and in Combination with Daptomycin against Daptomycin-Nonsusceptible Enterococcus faecium
Morrisette, T, Lev, KL, Canfield, GS, Duerkop, BA, Kebriaei, R, Stamper, KC, Holger, D, Lehman, SM, Willcox, S, Arias, CA & Rybak, MJ 2022, , Antimicrobial Agents and Chemotherapy, vol. 66, no. 1, e01623-21. https://doi.org/10.1128/AAC.01623-21

Emergence and Transmission of Daptomycin and Vancomycin-Resistant Enterococci Between Patients and Hospital Rooms
El Haddad, L, Hanson, BM, Arias, CA, Ghantoji, SS, Harb, CP, Stibich, M & Chemaly, RF 2021, , Clinical Infectious Diseases, vol. 73, no. 12, pp. 2306-2313. https://doi.org/10.1093/cid/ciab001

Evolution of Cefiderocol Non-Susceptibility in Pseudomonas aeruginosa in a Patient Without Previous Exposure to the Antibiotic
Streling, AP, Al Obaidi, MM, Lainhart, WD, Zangeneh, T, Khan, A, Dinh, AQ, Hanson, B, Arias, CA & Miller, WR 2021, , Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol. 73, no. 11, pp. e4472-e4474. https://doi.org/10.1093/cid/ciaa1909

Real World Long-term Assessment of The Efficacy of Tocilizumab in Patients with COVID-19: Results From A Large De-identified Multicenter Electronic Health Record Dataset in the United States
Nigo, M, Rasmy, L, May, SB, Rao, A, Karimaghaei, S, Kannadath, BS, De la Hoz, A, Arias, CA, Li, L & Zhi, D 2021, , International Journal of Infectious Diseases, vol. 113, pp. 148-154. https://doi.org/10.1016/j.ijid.2021.09.067

Impact of bicarbonate-ß-lactam exposures on methicillin-resistant staphylococcus aureus (Mrsa) gene expression in bicarbonate-ß-lactam-responsive vs. non-responsive strains
Ersoy, SC, Hanson, BM, Proctor, RA, Arias, CA, Tran, TT, Chambers, HF & Bayer, AS 2021, , Genes, vol. 12, no. 11, 1650. https://doi.org/10.3390/genes12111650

Evaluation of susceptibility testing methods for aztreonam and ceftazidime-avibactam combination therapy on extensively drug-resistant gram-negative organisms
Khan, A, Erickson, SG, Pettaway, C, Arias, CA, Miller, WR & Bhatti, MM 2021, , Antimicrobial Agents and Chemotherapy, vol. 65, no. 11, e00846-21. https://doi.org/10.1128/AAC.00846-21

Candida auris invasive infections during a COVID-19 case surge
Hanson, BM, Dinh, AQ, Tran, TT, Arenas, S, Pronty, D, Gershengorn, HB, Ferreira, T, Arias, CA & Shukla, BS 2021, , Antimicrobial Agents and Chemotherapy, vol. 65, no. 10, e01146-21, pp. e0114621. https://doi.org/10.1128/AAC.01146-21

Efficacy of omadacycline against multidrug-resistant enterococcus faecium Strains in a Mouse Peritonitis Model
Singh, KV, Arias, CA & Murray, BE 2021, , Antimicrobial Agents and Chemotherapy, vol. 65, no. 9, 00709. https://doi.org/10.1128/AAC.00709-21

Genomic analysis of carbapenem-resistant Pseudomonas aeruginosa ST143 clone showing susceptibility to broad-spectrum cephalosporins
Streling, AP, Cayô, R, Nodari, CS, Almeida, LGP, Santos, FF, Hanson, B, Dinh, AQ, Vasconcelos, ATR, Miller, WR, Arias, CA & Gales, AC 2021, , Journal of Global Antimicrobial Resistance, vol. 26, pp. 177-179. https://doi.org/10.1016/j.jgar.2021.05.019

Evaluation of the vitek 2, phoenix, and microscan for antimicrobial susceptibility testing of stenotrophomonas maltophilia
Khan, A, Arias, CA, Abbott, A, Bard, JD, Bhatti, MM & Humphries, RM 2021, , Journal of Clinical Microbiology, vol. 59, no. 9, e00654-21. https://doi.org/10.1128/JCM.00654-21